These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 678425)

  • 21. Immunologic control of the ascites of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells.
    Haagensen DE; Roloson G; Collins JJ; Wells SA; Bolognesi DP; Hansen HJ
    J Natl Cancer Inst; 1978 Jan; 60(1):131-9. PubMed ID: 628013
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumour sensitization obtained by injection of antigenic tumour cells into the caecal lumen of syngeneic mice.
    Laursen ML; Laursen K
    Eur J Cancer (1965); 1979 Apr; 15(4):537-42. PubMed ID: 436914
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibitory and stimulatory effect of spleen cells from tumour bearing animals on the growth of syngeneic tumour cells.
    Larsen FS; Spärck JV
    Acta Pathol Microbiol Scand C; 1978 Jun; 86C(3):131-9. PubMed ID: 716926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective tumor immunization induced by cells of elevated membrane-lipid microviscosity.
    Shinitzky M; Skornick Y; Haran-Ghera N
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5313-6. PubMed ID: 116228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytotoxic antibodies in the serum of C3H mice after inoculating them with spontaneous mammary gland tumor cells].
    Lavrovskiĭ VA; Viksler VKh
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Sep; (9):57-61. PubMed ID: 227196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro studies on splenocyte cytotoxicity against syngeneic mammary carcinomas of mice. 1. Reactivity of splenocytes from mice bearing mammary tumors against the corresponding and against other neoplasms.
    More R; Yron I; Weiss DW
    Isr J Med Sci; 1978 Jan; 14(1):146-61. PubMed ID: 204609
    [No Abstract]   [Full Text] [Related]  

  • 27. Protective effect of syngeneic antitumor serum on mammary tumor in a syngeneic host.
    Shinoda H; Yamazaki M; Mizuno D
    Gan; 1977 Oct; 68(5):561-5. PubMed ID: 590680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Competition for cytotoxic immune capacity against a 'syngeneic' mouse tumour distributed at two sites.
    Chassoux D; MacLennan IC; Munro TR
    Int J Cancer; 1977 Jun; 19(6):796-802. PubMed ID: 873644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune response to a syngeneic mammary adenocarcinoma. I. Comparison of kinetics of tumor cell growth and cytotoxic responses in syngeneic and allogeneic rats.
    Fortner GW; Kuperman O; Lucas ZJ
    J Immunol; 1975 Nov; 115(5):1269-76. PubMed ID: 1080776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.
    Milas L; Hunter N; Mason K; Withers HR
    Cancer Res; 1974 Jan; 34(1):61-71. PubMed ID: 4809463
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunization by the intestinal route of C3H-mice against C3H-L-ascites tumor cells.
    Laursen ML; Laursen K
    Proc Soc Exp Biol Med; 1977 Feb; 154(2):314-7. PubMed ID: 840870
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antitumor resistance induced by immunization with normal definitive tissues].
    Bodrova BL
    Tsitologiia; 1979 Nov; 21(11):1342-7. PubMed ID: 93333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on tumor-host relationship. V. Effect of myo-inositol on tumor cell growth in vivo and on the resistant activity of the host.
    Tanino T; Narumi K; Tsumita T
    Jpn J Exp Med; 1972 Dec; 42(6):575-82. PubMed ID: 4540908
    [No Abstract]   [Full Text] [Related]  

  • 34. Protective serum effects in tumor immunity.
    Vaage J
    Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inherent changes in the in vivo growth characteristics of C3H/He mammary carcinomas.
    Vaage J
    Cancer Res; 1980 Oct; 40(10):3495-3501. PubMed ID: 7438036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preferential generation of killer or helper T-lymphocyte activity directed to the tumour-associated transplantation antigens.
    Fujiwara H; Hamaoka T; Teshima K; Aoki H; Kitagawa M
    Immunology; 1976 Aug; 31(2):239-48. PubMed ID: 1085283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the induction of tolerance to alloantigens. II. The generation of serum factor(s) able to transfer alloantigen-specific tolerance for delayed-type hypersensitivity by portal venous inoculation with allogeneic cells.
    Fujiwara H; Qian JH; Satoh S; Kokudo S; Ikegami R; Hamaoka T
    J Immunol; 1986 Apr; 136(8):2763-8. PubMed ID: 2420865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cytotoxic antibodies against tumor cells in the blood of intact C3H mice].
    Lavrovskiĭ VA; Viksler VKh; Ustinov AS
    Biull Eksp Biol Med; 1979 May; 87(5):460-2. PubMed ID: 222378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The activity of nonspecific bone marrow and spleen suppressors in the latent period of tumor growth].
    Ogreba VI; Kusmartsev SA; Vasil'ev NV
    Vopr Onkol; 1988; 34(8):952-5. PubMed ID: 2971291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.